Tsui Elizabeth L, McDowell Hannah B, Laronda Monica M
Department of Pediatrics, Division of Endocrinology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
J Endocr Soc. 2024 Apr 15;8(6):bvae073. doi: 10.1210/jendso/bvae073. eCollection 2024 Apr 6.
The last 20 years have seen substantial improvements in fertility and hormone preservation and restoration technologies for a growing number of cancer survivors. However, further advancements are required to fill the gaps for those who cannot use current technologies or to improve the efficacy and longevity of current fertility and hormone restoration technologies. Ovarian tissue cryopreservation (OTC) followed by ovarian tissue transplantation (OTT) offers those unable to undergo ovarian stimulation for egg retrieval and cryopreservation an option that restores both fertility and hormone function. However, those with metastatic disease in their ovaries are unable to transplant this tissue. Therefore, new technologies to produce good-quality eggs and restore long-term cyclic ovarian function are being investigated and developed to expand options for a variety of patients. This mini-review describes current and near future technologies including in vitro maturation, in vitro follicle growth and maturation, bioprosthetic ovaries, and stem cell applications in fertility restoration research by their proximity to clinical application.
在过去20年里,越来越多癌症幸存者的生育能力以及激素保存和恢复技术有了显著进步。然而,仍需进一步改进,以填补那些无法使用现有技术人群的空白,或提高当前生育和激素恢复技术的疗效及持久性。卵巢组织冷冻保存(OTC)随后进行卵巢组织移植(OTT),为那些无法进行卵巢刺激以获取卵子并冷冻保存的人提供了一种恢复生育能力和激素功能的选择。然而,卵巢有转移性疾病的患者无法移植这种组织。因此,正在研究和开发生产优质卵子并恢复长期周期性卵巢功能的新技术,以扩大各类患者的选择范围。本综述通过与临床应用的接近程度,描述了当前和近期的技术,包括体外成熟、体外卵泡生长和成熟、生物假体卵巢以及干细胞在生育恢复研究中的应用。